4Suppliers
4Customers
1Debt Items
20Related Chains

United Therapeutics Corporation Suppliers

TickerNameConfidenceEvidence
CITIBANK-N-A CITIBANK-N-A 92% On March 9, 2026, the Company entered into two accelerated share repurchase agreements (the ASR Agreements ) with Citibank, N.A. ( Citi ) to repurchase approximately $1.5 billion in the aggregate of …
RAREGEN-LLC RAREGEN-LLC 80% In April 2019, Sandoz Inc. ( Sandoz ) and its marketing partner RareGen, LLC (now known as Liquidia PAH, LLC, a subsidiary of Liquidia Corporation) ( RareGen ), filed a complaint in the U.S. District…
SMITHS-MEDICAL-ASD-INC SMITHS-MEDICAL-ASD-INC 80% In April 2019, Sandoz Inc. ( Sandoz ) and its marketing partner RareGen, LLC (now known as Liquidia PAH, LLC, a subsidiary of Liquidia Corporation) ( RareGen ), filed a complaint in the U.S. District…
SUPN Supernus Pharmaceuticals, Inc. 72% Reciprocal relationship from SUPN graph: .e., at the time of sale to wholesalers/distributors). This liability is recorded as a reduction to gross product sales, and an increase in Accrued product re…

United Therapeutics Corporation Customers

TickerNameConfidenceEvidence
USGOV-DEPARTMENT-OF-JUSTICE USGOV-DEPARTMENT-OF-JUSTICE 95% USAspending awards from Department of Justice: $87,006 across 2 awards. 15B50525F00000191 OPSUMIT 10MG-QTY 4 @ $6,270.03 ADEMPAS 1MG, QTY 1 @ $12,153.05 REMODULIN 5MG/ML INJ 20ML VIAL, QTY 1 @ $6,206…
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS 95% USAspending awards from Department of Veterans Affairs: $651,394 across 8 awards. 36C26124N0646 TYVASO; 36C26024F0248 TYVASO; 36C26026F0064 TYVASO KITS & CARTRIDGES | Qwen corrected direction: Explic…
DISTRIBUTOR-1 DISTRIBUTOR-1 90% We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues.
DISTRIBUTOR-2 DISTRIBUTOR-2 90% We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues.

United Therapeutics Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
UTHR-DEBT-13272 Xbrl Convertible 90% xbrl convertible detail from xbrl 2016-12-31.

United Therapeutics Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for United Therapeutics Corporation.

United Therapeutics Corporation Ownership

HolderNameConfidenceEvidence
UTHR-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 90% 13F overlay lists Avoro Capital Advisors LLC as top holder; 859 tracked holders.

United Therapeutics Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
EMMA Emmaus Life Sciences, Inc. 100.00 2
GPCR Structure Therapeutics Inc. 100.00 2
SUPN Supernus Pharmaceuticals, Inc. 100.00 1 ['supplier']
GSK GSK plc 100.00 2
GOSS Gossamer Bio, Inc. 100.00 2
GWW W.W. Grainger, Inc. 100.00 2
LLY Eli Lilly and Company 100.00 2
JNJ Johnson & Johnson 100.00 2
AZN AstraZeneca PLC 100.00 2
NVSEF Novartis AG 100.00 2
CAH Cardinal Health, Inc. 100.00 2
MCK McKesson Corporation 100.00 2
ELV Elevance Health, Inc. 100.00 2
SANDOZ SANDOZ 50.00 2
FREJP FEDERAL HOME LOAN MORTGAGE CORP 50.00 2
ORANY ORANGE 50.00 2
SYY Sysco Corporation 50.00 2
BIIB Biogen Inc. 50.00 2
COLL Collegium Pharmaceutical, Inc. 50.00 2
FREVS First Real Estate Investment Trust of New Jersey, Inc. 50.00 2